Among the new proposed therapeutic approaches, stimulation of the endogenous secretion of glucagon-like peptides from enteroendocrine L-cells has been suggested [27] given the successful introduction of GLP-1-based drugs in the treatment of obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.